|
1
|
ILAE official report: a practical clinical definition of epilepsy.
|
Epilepsia
|
2014
|
7.12
|
|
2
|
Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies.
|
Epilepsia
|
2009
|
7.03
|
|
3
|
Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry.
|
Lancet Neurol
|
2011
|
3.93
|
|
4
|
ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes.
|
Epilepsia
|
2006
|
3.69
|
|
5
|
Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies.
|
Epilepsia
|
2008
|
2.74
|
|
6
|
Antiepileptic drug therapy: does mechanism of action matter?
|
Epilepsy Behav
|
2011
|
2.20
|
|
7
|
International consensus classification of hippocampal sclerosis in temporal lobe epilepsy: a Task Force report from the ILAE Commission on Diagnostic Methods.
|
Epilepsia
|
2013
|
1.82
|
|
8
|
Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs.
|
Lancet Neurol
|
2003
|
1.76
|
|
9
|
Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology.
|
Lancet Neurol
|
2009
|
1.73
|
|
10
|
Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes.
|
Epilepsia
|
2013
|
1.69
|
|
11
|
Idiosyncratic adverse reactions to antiepileptic drugs.
|
Epilepsia
|
2007
|
1.56
|
|
12
|
Vigabatrin and epilepsy: lessons learned.
|
Epilepsia
|
2007
|
1.55
|
|
13
|
Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.
|
Epilepsia
|
2012
|
1.52
|
|
14
|
Identification of new epilepsy treatments: issues in preclinical methodology.
|
Epilepsia
|
2012
|
1.45
|
|
15
|
Sertraline-induced potentiation of the CYP3A4-dependent neurotoxicity of carbamazepine: an in vitro study.
|
Epilepsia
|
2015
|
1.40
|
|
16
|
Cardiac function and antiepileptic drug treatment in the elderly: a comparison between lamotrigine and sustained-release carbamazepine.
|
Epilepsia
|
2009
|
1.38
|
|
17
|
Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: reply to Beyenburg et al., 2009.
|
Epilepsia
|
2010
|
1.37
|
|
18
|
Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X).
|
Epilepsy Res
|
2010
|
1.35
|
|
19
|
The ketogenic diet: from molecular mechanisms to clinical effects.
|
Epilepsy Res
|
2006
|
1.30
|
|
20
|
Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis.
|
Epilepsia
|
2011
|
1.27
|
|
21
|
Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI).
|
Epilepsy Res
|
2012
|
1.24
|
|
22
|
Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII).
|
Epilepsy Res
|
2006
|
1.23
|
|
23
|
An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly.
|
Epilepsia
|
2007
|
1.23
|
|
24
|
Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs.
|
Lancet Neurol
|
2003
|
1.20
|
|
25
|
Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments.
|
Epilepsia
|
2011
|
1.20
|
|
26
|
Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX).
|
Epilepsy Res
|
2008
|
1.20
|
|
27
|
Fetal exposure to GABA-acting antiepileptic drugs generates hippocampal and cortical dysplasias.
|
Epilepsia
|
2007
|
1.19
|
|
28
|
Add-on phenytoin fails to prevent early seizures after surgery for supratentorial brain tumors: a randomized controlled study.
|
Epilepsia
|
2002
|
1.17
|
|
29
|
Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy.
|
Epilepsia
|
2004
|
1.16
|
|
30
|
Genetic basis for idiosyncratic reactions to antiepileptic drugs.
|
Curr Opin Neurol
|
2009
|
1.10
|
|
31
|
EURAP: an international registry of antiepileptic drugs and pregnancy.
|
Epilepsia
|
2004
|
1.07
|
|
32
|
Revisiting phenobarbital for epilepsy.
|
BMJ
|
2004
|
1.07
|
|
33
|
Seizure control and treatment changes in pregnancy: observations from the EURAP epilepsy pregnancy registry.
|
Epilepsia
|
2013
|
1.07
|
|
34
|
Epilepsy after head injury.
|
Curr Opin Neurol
|
2004
|
1.06
|
|
35
|
Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII).
|
Epilepsy Res
|
2004
|
1.05
|
|
36
|
Antiepileptic drug selection for people with HIV/AIDS: evidence-based guidelines from the ILAE and AAN.
|
Epilepsia
|
2012
|
1.04
|
|
37
|
Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial.
|
Epilepsy Res
|
2003
|
1.01
|
|
38
|
Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy.
|
Epilepsia
|
2010
|
0.99
|
|
39
|
New and forthcoming anti-epileptic drugs.
|
Curr Opin Neurol
|
2011
|
0.97
|
|
40
|
Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs.
|
Epilepsia
|
2002
|
0.95
|
|
41
|
Treatment of epilepsy in developing countries.
|
BMJ
|
2007
|
0.94
|
|
42
|
Development of new treatment approaches for epilepsy: unmet needs and opportunities.
|
Epilepsia
|
2013
|
0.94
|
|
43
|
Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307.
|
Epilepsia
|
2014
|
0.93
|
|
44
|
Perampanel for adjunctive treatment of partial-onset seizures: a pooled dose-response analysis of phase III studies.
|
Epilepsia
|
2014
|
0.91
|
|
45
|
Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.
|
Basic Clin Pharmacol Toxicol
|
2005
|
0.90
|
|
46
|
Patterns of prescription of antiepileptic drugs in patients with refractory epilepsy at tertiary referral centres in Italy.
|
Epilepsy Res
|
2010
|
0.90
|
|
47
|
The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: A case-matched evaluation based on therapeutic drug monitoring data.
|
Epilepsy Res
|
2006
|
0.88
|
|
48
|
Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium.
|
Epilepsia
|
2006
|
0.87
|
|
49
|
Influence of aging on serum phenytoin concentrations: a pharmacokinetic analysis based on therapeutic drug monitoring data.
|
Epilepsy Res
|
2004
|
0.87
|
|
50
|
Novel medications for epilepsy.
|
Drugs
|
2011
|
0.86
|
|
51
|
Relative bioavailability and pharmacokinetics of two oral formulations of docosahexaenoic acid/eicosapentaenoic acid after multiple-dose administration in healthy volunteers.
|
Eur J Clin Pharmacol
|
2009
|
0.86
|
|
52
|
Improved enantioselective assay for the determination of fluoxetine and norfluoxetine enantiomers in human plasma by liquid chromatography.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2003
|
0.86
|
|
53
|
Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study.
|
CNS Drugs
|
2009
|
0.86
|
|
54
|
The long-term effect of vagus nerve stimulation on quality of life in patients with pharmacoresistant focal epilepsy: the PuLsE (Open Prospective Randomized Long-term Effectiveness) trial.
|
Epilepsia
|
2014
|
0.86
|
|
55
|
Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction.
|
J Clin Psychopharmacol
|
2002
|
0.86
|
|
56
|
Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update.
|
Clin Pharmacokinet
|
2013
|
0.85
|
|
57
|
Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder.
|
Ther Drug Monit
|
2006
|
0.84
|
|
58
|
Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine.
|
Epilepsia
|
2005
|
0.84
|
|
59
|
Analysis of topiramate and its metabolites in plasma and urine of healthy subjects and patients with epilepsy by use of a novel liquid chromatography-mass spectrometry assay.
|
Ther Drug Monit
|
2003
|
0.84
|
|
60
|
Changes in lamotrigine pharmacokinetics during pregnancy and the puerperium.
|
Ther Drug Monit
|
2008
|
0.84
|
|
61
|
A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy.
|
Epilepsia
|
2011
|
0.84
|
|
62
|
Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials.
|
Epilepsy Res
|
2005
|
0.83
|
|
63
|
Increased apparent oral clearance of valproic acid during intake of combined contraceptive steroids in women with epilepsy.
|
Epilepsia
|
2006
|
0.83
|
|
64
|
Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data.
|
Clin Pharmacokinet
|
2005
|
0.83
|
|
65
|
Treatment of status epilepticus in adults: guidelines of the Italian League against Epilepsy.
|
Epilepsia
|
2006
|
0.83
|
|
66
|
Pregabalin for the management of partial epilepsy.
|
Neuropsychiatr Dis Treat
|
2008
|
0.83
|
|
67
|
A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy.
|
Epilepsia
|
2011
|
0.83
|
|
68
|
Commentary: Epilepsy is a Global Problem.
|
Epilepsia
|
2014
|
0.83
|
|
69
|
Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders.
|
CNS Drugs
|
2009
|
0.82
|
|
70
|
Serum carbamazepine concentrations in elderly patients: a case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data.
|
Epilepsia
|
2003
|
0.82
|
|
71
|
Antiepileptic drugs and brain maturation: fetal exposure to lamotrigine generates cortical malformations in rats.
|
Epilepsy Res
|
2007
|
0.82
|
|
72
|
Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: sources of variability and preliminary observations on relations with clinical response.
|
Ther Drug Monit
|
2002
|
0.81
|
|
73
|
A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy.
|
Epilepsia
|
2005
|
0.81
|
|
74
|
Plasma gabapentin concentrations in children with epilepsy: influence of age, relationship with dosage, and preliminary observations on correlation with clinical response.
|
Ther Drug Monit
|
2003
|
0.81
|
|
75
|
Rapid onset of seizure suppression with pregabalin adjunctive treatment in patients with partial seizures.
|
Epilepsia
|
2009
|
0.81
|
|
76
|
Influence of enzyme inducing antiepileptic drugs on the pharmacokinetics of levetiracetam in patients with epilepsy.
|
Epilepsy Res
|
2011
|
0.80
|
|
77
|
Measurement of seizure freedom in adjunctive therapy studies in refractory partial epilepsy: the levetiracetam experience.
|
Epileptic Disord
|
2006
|
0.80
|
|
78
|
Pharmacology of antiepileptic drugs during pregnancy and lactation.
|
Epilepsy Behav
|
2007
|
0.80
|
|
79
|
When the past challenges the present: are older antiepileptic drugs still the best choice in childhood absence epilepsy?
|
Lancet Neurol
|
2010
|
0.80
|
|
80
|
Novel frontiers in epilepsy treatments: preventing epileptogenesis by targeting inflammation.
|
Expert Rev Neurother
|
2013
|
0.80
|
|
81
|
CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.
|
Expert Opin Drug Metab Toxicol
|
2015
|
0.80
|
|
82
|
Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: reply to Costa et al.
|
Epilepsia
|
2011
|
0.79
|
|
83
|
The Written Declaration on Epilepsy: an important achievement for Europe and beyond.
|
Seizure
|
2011
|
0.78
|
|
84
|
Preclinical activity profile of α-lactoalbumin, a whey protein rich in tryptophan, in rodent models of seizures and epilepsy.
|
Epilepsy Res
|
2011
|
0.78
|
|
85
|
Translating monotherapy trials into clinical practice: a look into the abyss.
|
Epilepsy Behav
|
2003
|
0.78
|
|
86
|
Addressing overtreatment in patients with refractory epilepsy at a tertiary referral centre in Brazil.
|
Epileptic Disord
|
2011
|
0.78
|
|
87
|
The pharmacology of new antiepileptic drugs: does a novel mechanism of action really matter?
|
CNS Drugs
|
2011
|
0.77
|
|
88
|
Old versus new antiepileptic drugs: the SANAD study.
|
Lancet
|
2007
|
0.77
|
|
89
|
NICE guidance on newer drugs for epilepsy in adults.
|
BMJ
|
2004
|
0.77
|
|
90
|
Italian consensus conference on epilepsy and pregnancy, labor and puerperium.
|
Epilepsia
|
2009
|
0.76
|
|
91
|
Characteristics of a large population of patients with refractory epilepsy attending tertiary referral centers in Italy.
|
Epilepsia
|
2010
|
0.76
|
|
92
|
Antiepileptic drug therapy: does mechanism of action matter?
|
Epilepsy Behav
|
2011
|
0.76
|
|
93
|
The impact of enzyme-inducing antiepileptic drugs on antiretroviral drug levels: a case-control study.
|
Epilepsy Res
|
2012
|
0.76
|
|
94
|
Off-label prescribing of antiepileptic drugs in pharmacoresistant epilepsy: a cross-sectional drug utilization study of tertiary care centers in Italy.
|
CNS Drugs
|
2014
|
0.76
|
|
95
|
Epilepsy in elderly people: management issues.
|
Epileptic Disord
|
2002
|
0.76
|
|
96
|
Interlaboratory variability in the quantification of new generation antiepileptic drugs based on external quality assessment data.
|
Epilepsia
|
2003
|
0.76
|
|
97
|
Development and validation of an HPLC-UV detection assay for the determination of rufinamide in human plasma and saliva.
|
Anal Bioanal Chem
|
2011
|
0.76
|
|
98
|
A novel enantioselective microassay for the high-performance liquid chromatography determination of oxcarbazepine and its active metabolite monohydroxycarbazepine in human plasma.
|
Ther Drug Monit
|
2007
|
0.75
|
|
99
|
Major birth defects after exposure to newer-generation antiepileptic drugs.
|
JAMA
|
2011
|
0.75
|
|
100
|
Hormone replacement therapy in women with epilepsy.
|
Epilepsia
|
2007
|
0.75
|
|
101
|
The International League Against Epilepsy at the threshold of its second century: year 2.
|
Epilepsia
|
2012
|
0.75
|
|
102
|
Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response.
|
Ther Drug Monit
|
2003
|
0.75
|
|
103
|
The International League Against Epilepsy at the threshold of its second century: year 1.
|
Epilepsia
|
2011
|
0.75
|
|
104
|
Antiepileptic drugs and quality of life in the elderly: results from a randomized double-blind trial of carbamazepine and lamotrigine in patients with onset of epilepsy in old age.
|
Epilepsy Behav
|
2010
|
0.75
|
|
105
|
Development and Validation of an HPLC-UV Assay for the Therapeutic Monitoring of the New Antiepileptic Drug Perampanel in Human Plasma.
|
Ther Drug Monit
|
2016
|
0.75
|
|
106
|
Active control trials: endpoints beyond conventional efficacy and tolerability measures.
|
Epilepsy Res
|
2006
|
0.75
|
|
107
|
Evaluations and awards at the fifth European Congress of Epileptology, Madrid, 6-10 October 2002.
|
Epilepsia
|
2004
|
0.75
|
|
108
|
In Memoriam: Hanneke De Boer (1946-2015).
|
Epilepsia
|
2016
|
0.75
|
|
109
|
Phenobarbital pharmacokinetics in old age: a case-matched evaluation based on therapeutic drug monitoring data.
|
Epilepsia
|
2005
|
0.75
|
|
110
|
Introduction to the clinical definition of epilepsy by the ILAE president.
|
Epilepsia
|
2014
|
0.75
|
|
111
|
Commentary: why an international epilepsy day?
|
Epilepsia
|
2014
|
0.75
|
|
112
|
Challenges in the pharmacotherapy of the epilepsies.
|
Expert Rev Neurother
|
2002
|
0.75
|
|
113
|
A new classification is born.
|
Epilepsia
|
2017
|
0.75
|
|
114
|
Stereoselective determination of vigabatrin enantiomers in human plasma by high performance liquid chromatography using UV detection.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2007
|
0.75
|
|
115
|
Can people with epilepsy enjoy sports?
|
Epilepsy Res
|
2011
|
0.75
|
|
116
|
The remarkable story of valproic acid.
|
Lancet Neurol
|
2016
|
0.75
|
|
117
|
Epileptic Disorders to become the educational journal of the ILAE.
|
Epileptic Disord
|
2013
|
0.75
|